Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2026 Jun 22;17:1911100. doi: 10.3389/fimmu.2026.1911100

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

Jiashun Li 1, Ainikaer Abulaiti 1, Deyu Li 1, Yan Zhao 1, Paerhati Wahafu 1, Maerdan Maimaitiming 1, Shi Qiu 1, Yuxiang Zhang 2, Yaqin An 1, Wenxing Wang 1, Liangquan Shi 1, Maihemuti Yakufu 1,*, Li Shu 1,*, Guohua Li 1,*, Zhen Liu 1,*
PMCID: PMC13334270  PMID: 42441036

In the published article, there was an error in the Funding statement. The Funding statement was incorrectly published as:

“This work was financially supported by the Health Care and Medical Research Special Project of Xinjiang Uygur Autonomous Region (BL202675, BL202573, BL202460), Youth Medical Science and Technology Talent Special Research Project (WJWY-202331), National Natural Science Foundation of China (82460420), Research and Innovation Team Project, Xinjiang Medical University (XYD2024C12), Tianshan Talent Training Program (TSYC202301B039, TSYC202301B077 and TSYC202301B106), Key Laboratory of High Incidence Disease Research in Xinjiang (Xinjiang Medical University), Ministry of Education (2023B04), Natural Science.”

The correct Funding statement reads:

“This work was financially supported by the Health Care and Medical Research Special Project of Xinjiang Uygur Autonomous Region (BL202675, BL202573, BL202460), Youth Medical Science and Technology Talent Special Research Project (WJWY-202331), National Natural Science Foundation of China (82460420), Research and Innovation Team Project, Xinjiang Medical University (XYD2024C12), Tianshan Talent Training Program (TSYC202301B039, TSYC202301B077 and TSYC202301B106), Key Laboratory of High Incidence Disease Research in Xinjiang (Xinjiang Medical University), Ministry of Education (2023B04), Natural Science Foundation of Xinjiang Uygur Autonomous Region (2022D01C821), Research and Innovation Team Project, Sixth Affiliated Hospital of Xinjiang Medical University (LFYKYZXJJ2024001), Tianshan Innovation Team Program (2025D14019), and Tianshan District Science & Technology Development Program (WLMQTSQ-2025-KJXM05).”

The original version of this article has been updated.

This correction does not change the scientific conclusions of the article in any way.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES